Arvinas Inc(ARVN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.18 | Insider Own | 10.38% | Shs Outstand | 65.5M | Perf Week | -4.83% |
| Market Cap | 0.46B | Forward P/E | - | EPS next Y | -299370.68% | Insider Trans | -0.79% | Shs Float | 58.6M | Perf Month | -4.96% |
| Enterprise Value | -0.09B | PEG | - | EPS next Q | -0.79 | Inst Own | 80.3% | Short Float | 9.54% | Perf Quarter | -15.6% |
| Income | -0.01B | P/S | 1.68 | EPS this Y | 99.91% | Inst Trans | 1.68% | Short Ratio | 6.72 | Perf Half Y | -33.18% |
| Sales | 0.28B | P/B | 0.9 | EPS next 5Y | - | ROA | -1.31% | Short Interest | 5.59M | Perf YTD | -40.22% |
| Book/sh | 7.84 | P/C | 0.83 | EPS past 3/5Y | 40.13% 17.7% | ROE | -1.76% | 52W High | -51.14% ($14.51) | Perf Year | -27.06% |
| Cash/sh | 8.54 | P/FCF | - | Sales past 3/5Y | 25.96% 64.5% | ROIC | -1.83% | 52W Low | 5.19% ($6.74) | Perf 3Y | -59.53% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 81.44% | Gross Margin | 96.69% | Volatility(W/M) | 7.35% 5.35% | Perf 5Y | -92.4% |
| Dividend TTM | - | EV/Sales | -0.32 | Sales Y/Y TTM | -11.85% | Oper. Margin | -10.1% | ATR (14) | 0.41 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.91 | EPS Q/Q | -71.89% | Profit Margin | -3.45% | RSI (14) | 41.08 | Recom | 2.13 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.39 | Sales Q/Q | -98.81% | SMA20 | -4.23% ($7.4) | Beta | 1.8 | Target Price | $14.15 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/11/3 | SMA50 | -11.59% ($8.02) | Rel Volume | 2.17 | Prev Close | $7.52 |
| Employees | 246 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 10.65% -95.96% | SMA200 | -26.43% ($9.64) | Avg Volume(3M) | 0.83M | Price | $7.09 |
| IPO | 2018/9/27 | Option/Short | Yes/Yes | Trades | 11511 | Volume | 1,802,294 | Change | -5.72% |
A clinical-stage biopharmaceutical company developing targeted therapeutics based on a PROTAC platform that leverages the body's natural protein degradation system to eliminate disease-causing proteins. Building on its groundbreaking targeted protein degradation (TPD) technology, the company focuses on developing treatments for breast cancer and neurodegenerative diseases—conditions that have historically been difficult to address with traditional small-molecule compounds—and is validating the potential of its pipeline through multiple strategic partnerships.
Over the past 1 year, on the lower side
51% below its 1-year high.
Traded more than usual. That is 217% of its average volume.
ARVN has a sound balance sheet but weak earning power
Of every $100 in sales, $10.10 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +99.9% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $168. Peers typically go for $1,242.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -92.4%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 80.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #225 of 597 in the industry
Based on market cap of $464M.
FAQ
What kind of company is ARVN?
ARVN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ARVN?
The market cap of ARVN is approximately $464M, ranking 3,204 within its sector.
What is the 52-week high and low for ARVN?
ARVN has recorded a 52-week high of $14.51 and a low of $6.74.
